La catena delle opzioni mostra i dati chiave delle opzioni azionarie di NeuroBo Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per NeuroBo Pharmaceuticals..

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Azioni, Catena delle Opzioni

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals Inc

Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report). The associated price ta...

Buy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental Pipeline

NeuroBo Pharmaceuticals GAAP EPS of -$1.85

NeuroBo Pharmaceuticals ( ($NRBO) ) just unveiled an update. NeuroBo Pharmaceuticals, Inc. has announced promising results from Part 1 of the Phase...

NeuroBo's DA-1726 Shows Promise in Obesity Trial Phase 1

An announcement from NeuroBo Pharmaceuticals ( ($NRBO) ) is now available. NeuroBo Pharmaceuticals, Inc. has updated its corporate presentation on ...

NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

NeuroBo Pharmaceuticals GAAP EPS of -$0.55 beats by $0.18

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report). The associated price ta...

NeuroBo Pharmaceuticals: Promising MASH and Obesity Treatment Pipeline Driving Buy Rating

NeuroBo Pharmaceuticals (NRBO) announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia ...

NeuroBo Pharmaceuticals announces relignment, change name

NeuroBo Pharmaceuticals ( ($NRBO) ) just unveiled an update. NeuroBo Pharmaceuticals is set to rebrand as MetaVia Inc. on November 29, 2024, with a...

NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report), retaining the price target of $1...

NeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthy

ADBE

ALLY

BLNK

BYDDF

CAPR

CTRI

CYTK

IBTA

INTC

LNVGY

MIRM

MSFT

MTEN

NAPA

NFLX

NRBO

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SRRK

TSLA

ULTA

USGO

VANI

VLKAF

VRSSF

Press Releases

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Earnings

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Cyclo Therapeutics

Forte Biosciences

GlycoMimetics

iBio

IN8bio

Kairos Pharma

MEI Pharma

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Nanoviricides

Pieris Pharmaceuticals, Inc. - Common Stock

Pieris Pharmaceuticals

Palatin Techs

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Spruce Biosciences

Synlogic

Tenax Therapeutics

Unity Biotechnology

Maxim Group

Ladenburg Thalmann

Comments

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals (NRBO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO